Vaccine effects on in-hospital COVID-19 outcomes.
Gonçalves BP. et al, (2025), Epidemiology (Cambridge, Mass.)
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2025), The Lancet Infectious Diseases
Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.
Laidlaw SM. et al, (2025), Microbiology spectrum, 13
‘Involve those who are managing these outbreaks’: stakeholders’ perspectives on the barriers and facilitators to the implementation of clinical management guidelines for high-consequence infectious diseases in Uganda—a thematic network analysis
Kabajaasi O. et al, (2025), BMJ Public Health, 3, e001165 - e001165
Europe needs a sustainably funded influenza research and response network.
Krammer F. et al, (2025), The Lancet. Infectious diseases
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.
Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33
Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Kasbergen LMR. et al, (2025), The Lancet Infectious Diseases
Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Sigfrid L. et al, (2025), The Lancet Infectious Diseases
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Ebola disease: bridging scientific discoveries and clinical application.
Rojek A. et al, (2024), The Lancet. Infectious diseases
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Group sequential designs for clinical trials when the maximum sample size is uncertain.
Yarahmadi A. et al, (2024), Stat Med
Presentation and outcomes of Lassa fever in children in Nigeria: a prospective cohort study (LASCOPE).
Duvignaud A. et al, (2024), Journal of the Pediatric Infectious Diseases Society
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.
Randremanana RV. et al, (2024), Trials, 25
Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms
Citarella BW. et al, (2024), Heliyon, 10, e29591 - e29591
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.
Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
Peto L. et al, (2024), Lancet (London, England), 403, 1339 - 1340
Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
Bourner J. et al, (2024), PloS one, 19
Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity
Swets MC. et al, (2023), Nature Communications, 14